ARIVIS AG
Desconocido
DESIREE: Decision Support and Information Management System for Breast Cancer
ARIVIS AG
participó en un
H2020:
H2020-PHC-2014-2015
Breast cancer is the most common type of cancer affecting woman in the EU. Multidisciplinary Breast Units (BUs) were introduced in order to...
2015-11-10 - 2019-07-31 | Financiado
2015-11-10 - 2019-07-31 | Financiado
Phd: Deciphering PI3K biology in health and disease
ARIVIS AG
participó en un
H2020:
H2020-MSCA-ITN-2015
The Phosphoinositide 3-kinase (PI3K) pathway is at the core of multiple fundamental biological processes controlling metabolism, protein syn...
2015-08-07 - 2019-10-31 | Financiado
2015-08-07 - 2019-10-31 | Financiado
RELEVANCE: Regulation of red cell life span erythropoiesis survival senescence and clearance
ARIVIS AG
participó en un
H2020:
H2020-MSCA-ITN-2015
Anaemia is the most common pathological condition affecting 1.6 billion individuals worldwide. It thus presents a serious health care proble...
2015-08-03 - 2019-11-30 | Financiado
2015-08-03 - 2019-11-30 | Financiado
COMMITMENT: Combined Molecular Microscopy for Therapy and Personalized Medication in Rare Anaemias Treatments
ARIVIS AG
participó en un
FP7:
The aim of CoMMiTMenT is the development of combined imaging technologies based on optofluidic microscopy and scanning ion conductance micro...
Financiado
Financiado
* No se disponen de datos de la empresa actual.